ReviewChinese neurosurgical journal2021
Expert consensus on drug treatment of chronic subdural hematoma.
Review in Chinese neurosurgical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Effectiveness of tranexamic acid on chronic subdural hematoma recurrence: a meta-analysis and systematic review.Frontiers in neurology · 2024Pooled it
- Effectiveness Comparisons of Drug Therapy on Chronic Subdural Hematoma Recurrence: A Bayesian Network Meta-Analysis and Systematic Review.Frontiers in pharmacology · 2022Pooled it
- Naoxueshu Oral Liquid Promotes Hematoma Absorption and Relieves Neurological Symptoms in Chronic Subdural Hematoma Patients: A Prospective, Single-Arm, Self-Controlled Study.Chinese journal of integrative medicine · 2026Article
- Reinitiating antiplatelet therapy in chronic subdural hematoma: Does adjunctive middle meningeal artery embolization improve outcomes?Neurosurgical review · 2026Article
- Pathophysiology of chronic subdural hematoma-new insights.Therapeutic advances in neurological disorders · 2026Review
- Article
- Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment: A Guideline from the Society of Vascular and Interventional Neurology Guidelines and Practice Standards Committee.Stroke (Hoboken, N.J.) · 2025Review
- Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019-2024.The Lancet regional health. Western Pacific · 2025Article
- Efficacy of atorvastatin-based treatment in super-aged patients with chronic subdural hematoma: a case series and literature review.Frontiers in neurology · 2025Article
- Predictive value of temporal muscle thickness in patients with chronic subdural hematoma.Frontiers in neurology · 2025Article
- A Case Report of Tranexamic Acid for the Treatment of Chronic Subdural Hematoma in an 86-Year-Old Patient.Cureus · 2024Article
- Establishment and validation of a CT-based prediction model for the good dissolution of mild chronic subdural hematoma with atorvastatin treatment.Neuroradiology · 2024Article
- Development and internal validation of a nomogram to predict temporary acute agitated delirium after surgery for chronic subdural hematoma in elderly patients: an analysis of the clinical database.Frontiers in neurology · 2024Article
- Biofluid Biomarkers in the Prognosis of Chronic Subdural Hematoma: A Systematic Scoping Review.Diagnostics (Basel, Switzerland) · 2023Article
- Middle Meningeal Artery Embolization in the Management of Chronic Subdural Hematoma: a Comprehensive Review of Current Literature.Current neurology and neuroscience reports · 2023Review
- A bibliometric analysis of chronic subdural hematoma since the twenty-first century.European journal of medical research · 2022Article
- Determination of a 'point of no return' in refractory chronic subdural hematomas: A case report and review of the literature.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.